Breadcrumb
IRA Resource Center
The Inflation Reduction Act (IRA) was signed into law on Aug. 16, 2022. Among the topics covered by the IRA are Medicare price negotiation for qualifying single-source drugs; manufacturer rebates for certain drugs paid under Medicare Parts B or D if their average prices increase faster than the rate of inflation; Part D redesign including eliminating the coverage gap, setting an annual out-of-pocket cap (initially $2,000), limits to premium increases, mandated coverage for vaccines, and a $35 monthly insulin cap. Many questions remain about the implementation of this law, which will be done through agency guidance, program instruction, agreements between CMS and drug manufacturers, and notice-and-comment rulemaking.
Special IRA Edition of JMCP
To learn about the impacts of the Inflation Reduction Act in the Journal of Managed Care + Specialty Pharmacy view the special IRA edition on JMCP.org.
Additional AMCP Resources
- AMCP Statement on the Passage of the Inflation Reduction Act
- Understanding the Fundamentals of IRA and Its Impact, AMCP Nexus Pre-Conference Program
- Keeping Up With IRA at E-Learning Days
- IRA Workshop Series
JMCP Articles on the Drug Price Negotiation Program
- Striving for Affordable Medicine: Lessons in Price Negotiation Learned from the United Kingdom
- Sociodemographic and Spending Characteristics of Medicare Beneficiaries Taking Prescription Drugs Subject to Price Negotiations
- Using A Patient-Centered Value Assessment to Optimize Fair Prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program
- Drugs Likely Subject to Medicare Negotiation, 2026-2028
- Estimated Discounts Generated by Medicare Drug Negotiation in 2026
- PhARMA Foundation Challenge Award Winners:
- Medicare Drug Price Negotiation: The Complexities of Selecting Therapeutic Alternatives for Estimating Comparative Effectiveness
- Identifying Therapeutic Alternatives in CMS Drug Negotiation: The Case of Etanercept
- Evidence Inventory: A Patient-Centered Methodological Framework for CMS to Assess the Clinical Benefit of Drugs to Inform Maximum Fair Price Negotiation
CMS Resources
- CMS Drug Price Negotiation Timeline for 2026
- ASPE Office of Health Policy: Fact Sheet — Inflation Reduction Act Research Series— Medicare Enrollees’ Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program
- Inflation Reduction Act and Medicare
- Fact Sheet: Anniversary of the Inflation Reduction Act: Update on CMS Implementation
- Fact Sheet: Medicare Drug Price Negotiation Program Initial Guidance
- Press Release: Inflation Reduction Act Continues to Lower Out-of-Pocket Prescription Drug Costs for Drugs with Price Increases Above Inflation
- FAQs: Reduced Drug Prices, Enhanced Medicare Benefits Under the Inflation Reduction Act
AMCP Regulatory NewsBREAKS
Find IRA-related breaking news on the member-only Regulatory NewsBREAKs page.
Legislation
For questions, please contact Vicky Jucelin.